There are 2789 resources available
259P - Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
Presenter: Michaela Tsai
Session: ePoster Display
260P - High enrichment of ATRX mutations in lung and liver metastasis of breast cancer
Presenter: Rongrong Chen
Session: ePoster Display
1008P - cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility
Presenter: Mithun Khattar
Session: ePoster Display
1009P - Current strategies of cell and gene therapy for solid tumors: Preliminary results of the joint international ESMO and EBMT Cell Therapy and Immunobiology Working Party questionnaire-based survey
Presenter: Patrizia Comoli
Session: ePoster Display
1010P - Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008
Presenter: Thomas Eigentler
Session: ePoster Display
1011P - FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
Presenter: Aung Naing
Session: ePoster Display
1012P - Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade
Presenter: WON SUK LEE
Session: ePoster Display
1013P - Similar overall survival in tebentafusp-treated 2L+ metastatic uveal melanoma regardless of prior immunotherapy
Presenter: Josep M. Piulats
Session: ePoster Display
1053P - Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Presenter: Timothy Humphries
Session: ePoster Display
1054P - FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma
Presenter: Florentia Dimitriou
Session: ePoster Display